English 
Español
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody.
Related Articles
-
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. SHOW MORE
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
UDIBI
Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. SHOW MORE
-
UDIBI
Published: February 27, 2023 Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™ More information
-
UDIBI
Published: August 28, 2022 Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies More information
-
UDIBI
An international comparative analysis and roadmap to sustainable biosimilar markets. SHOW MORE
-
UDIBI
Published: September 6, 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a...
0 Comments
